Irish Amarin announces 70 million-dollar placement


Dublin – Amarin Corporation plc today announced it has entered into an agreement with a number of investors for a $70 million private placement. The placement of units for $70 million consists of $66.4 million in cash proceeds and $3.6 million from the conversion of convertible bridge notes. In consideration for the $66.4 million cash payment, Amarin will issue 66.4 million units. Each unit has a purchase price of $1.00 and consists of one American Depositary Share and a warrant for the purchase of 0.50 of an ADS. The warrants will have a five year term and an exercise price of $1.50 per ADS. In consideration for the conversion of the principal amount of $3.6 million of convertible bridge notes, Amarin will issue 4 million units. In accordance with the terms of the conversion of the bridge notes, each unit has a purchase price of $0.90 and consists of one ADS and a warrant for the purchase of 0.50 of an ADS. The warrants will also have a five-year term and an exercise price of $1.50 per ADS.
The company has said it will use the money to progress phase III testing through to an NDA filing of its prescription-grade omega-3 fatty acid drug AMR101 (a ethyl ester of eicosapentaenoic acid) in patients with hyperglyceridemia and mixed dyslipidemia. The funding will also be used for the retirement of $1.9 million in bridge financing and for general corporate purposes.



While on a trip to strengthen economic ties between Ireland and California, Ireland's minister for jobs, enterprise and innovation, Richard Bruton, revealed on 15 March that two Irish government organisations have provided...



Dublin – Irish drugmaker Shire plc has agreed to pay US-$100m in upfront for Ferrokin Biosciences Inc., a San Francisco-based specialist for iron chelation therapies. US-$225m could be added if certain milestones are achieved....



Abbott Laboratories is to spend a85m and expand its pharmaceutical manu­facturing facility in Sligo (Ireland), saying that would help the company to ensure its supply of compounds in bio­pharmaceutical areas like virology and...



Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the...



Dublin/Cambridge – The University of Cambridge and Irish drugmaker Elan Pharmaceutical Inc. have joined forces in the battle against Alzheimer’s Disease. Together, the two will create the Cambridge-Elan Centre for Research...



Uppsala/Craigavon - Irish Almac trusts a Swedish platform to develop new cancer drug candidates. As Uppsala-based Beactica announced on Tuesday, its Sprint-technology will be used to identify fragment hits against a number of...



Dublin /New York – Irish Tibotec Pharmaceutical Ltd and Bristol-Myers Squibb (BMS) have entered into a clinical collaboration for the treatment of chronic hepatitis C infections with a combination of BMS’ NS5A replication complex...



Athlone – Biopharma group Alkermes has established its new Irish corporate base following its merger with Elan Drug Tech­nologies. The a712m (US$960m) deal agreed back in May – which saw Alkermes acquire Elan’s Athlone-based drug...

Displaying results 1 to 10 out of 49

1-10 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues